Computational Investigation of Withaferin A as a Potential Inhibitor of Epstein–Barr Virus Nuclear Antigen 1 (EBNA1): Molecular Docking and ADMET Analysis
Journal of Health and Biology · 2026
DOI: 10.71428/jhb.2026.0212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Health and Biology, 2026. Verfasst von Mohammed Hammood.
Abstract (Originalsprache)
Background
Epstein–Barr virus (EBV) is an oncogenic herpesvirus associated with several human cancers. Epstein–Barr nuclear antigen 1 (EBNA1), essential for viral latency and episome maintenance, represents a promising therapeutic target.
Aim
To evaluate the binding affinity and predicted pharmacokinetic properties of Withaferin A, a natural steroidal lactone from Withania somnifera, against EBV EBNA1 using molecular docking and ADMET analysis.
Methods
Withaferin A was docked against EBNA1 (PDB ID: 6NPP) using SwissDock and compared with the reference ligand KWG. Protein–ligand interactions were analyzed using BIOVIA Discovery Studio and PyMOL, while ADMET-AI was used to predict pharmacokinetic and toxicity properties.
Results
Withaferin A showed stronger predicted binding affinity toward EBNA1 than the reference ligand KWG, with a minimum binding energy of −6.866 kcal/mol and an average docking score of −5.193 ± 0.727 kcal/mol, compared with −5.494 kcal/mol and −4.465 ± 0.435 kcal/mol for KWG, respectively. Withaferin A formed multiple hydrophobic interactions with key EBNA1 residues, including Phe508, Tyr510, Leu539, Pro540, Met563, Thr596, Cys598, Phe600, and Val604. ADMET analysis indicated favorable drug-likeness, intestinal absorption, oral bioavailability, and safety. Despite moderate CYP3A4 and P-glycoprotein inhibition, Withaferin A showed lower predicted risks of liver injury (0.32 vs 0.97) and carcinogenicity (0.03 vs 0.38) than the reference ligand.
Conclusion
Withaferin A demonstrates promising computational activity against EBNA1, with favorable binding and ADMET properties, suggesting its potential as a lead compound for EBV-associated cancer therapy. Further molecular dynamics, in vitro, and in vivo studies are required for validation.
Zitieren
APA
Hammood, M. (2026). Computational Investigation of Withaferin A as a Potential Inhibitor of Epstein–Barr Virus Nuclear Antigen 1 (EBNA1): Molecular Docking and ADMET Analysis. Journal of Health and Biology. https://doi.org/10.71428/jhb.2026.0212
Vancouver
Hammood M. Computational Investigation of Withaferin A as a Potential Inhibitor of Epstein–Barr Virus Nuclear Antigen 1 (EBNA1): Molecular Docking and ADMET Analysis. Journal of Health and Biology. 2026. doi:10.71428/jhb.2026.0212
BibTeX
@article{Hammood2026,
author = {Hammood, Mohammed},
title = {Computational Investigation of Withaferin A as a Potential Inhibitor of Epstein–Barr Virus Nuclear Antigen 1 (EBNA1): Molecular Docking and ADMET Analysis},
journal = {Journal of Health and Biology},
year = {2026},
doi = {10.71428/jhb.2026.0212}
}
EUVIMED